US 12,503,469 B2
Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
Birgit Keil, Duesseldorf (DE); Franz-Josef Mais, Duesseldorf (DE); Winfried Joentgen, Cologne (DE); and Alfons Grunenberg, Wuppertal (DE)
Assigned to Adverio Pharma GmbH, Leverkusen (DE)
Filed by Adverio Pharma GmbH, Leverkusen (DE)
Filed on Nov. 15, 2021, as Appl. No. 17/526,129.
Application 17/526,129 is a continuation of application No. 16/848,249, filed on Apr. 14, 2020, granted, now 11,203,593.
Application 16/848,249 is a continuation of application No. 16/119,671, filed on Aug. 31, 2018, granted, now 10,662,188, issued on May 26, 2020.
Application 16/119,671 is a continuation of application No. 15/672,921, filed on Aug. 9, 2017, granted, now 10,087,183, issued on Oct. 2, 2018.
Application 15/672,921 is a continuation of application No. 14/769,334, abandoned, previously published as PCT/EP2014/053096, filed on Feb. 18, 2014.
Claims priority of application No. 2806895 (CA), filed on Feb. 21, 2013; and application No. 2807859 (CA), filed on Feb. 21, 2013.
Prior Publication US 2022/0073515 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/519 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/519 (2013.01)] 5 Claims
 
1. A pharmaceutical composition comprising a compound of the formula (I)

OG Complex Work Unit Chemistry
and a pharmaceutically acceptable carrier, in which 100 percent by weight relative to the total weight of all forms of the compound of formula (I) in the composition is in crystalline form of Modification (I), wherein the compound of the formula (I) is characterized by an X-Ray powder diffractogram comprising peak maxima of the 2 Theta angle of 6.7, 9.1 and 17.8.